Company: SMNR
Filing Date: 2025-08-22
Form Type: 8-K
Source: 0001213900-25-079504
Chunk: 5

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-22
Form: 8-K
Item: Item 3.02
Chunk 5
---
 of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Item
9.01. Financial Statement and Exhibits.

(d)
Exhibits.

  Exhibit      Description                                                                                                                                                             
  No.                                                                                                                                                                                  
  10.1*        Securities Purchase Agreement, dated as of August 20, 2025, by and among Denali Capital Acquisition Corp., Semnur Pharmaceuticals, Inc., and the Buyers party thereto.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  104          Cover Page Interactive Data File (embedded within the                                                                                                                   

  Certain                                                                                                                                

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

                             DENALI CAPITAL ACQUISITION CORP.                               
  Date: August 21, 2025      By:                                   /s/ Lei Huang            
                             Name:                                 Lei Huang                
                             Title:                                Chief Executive Officer